Disclosed Amino Acid Sequence Derived From Virus Patents (Class 424/186.1)
-
Patent number: 10857224Abstract: The present invention provides compositions and methods related to equine live-attenuated influenza vaccines.Type: GrantFiled: June 2, 2017Date of Patent: December 8, 2020Assignee: University of RochesterInventor: Luis Martinez-Sobrido
-
Patent number: 10844097Abstract: The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered influenza B hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple influenza B viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.Type: GrantFiled: June 2, 2017Date of Patent: November 24, 2020Assignee: Sanofi Pasteur Inc.Inventors: Tod Strugnell, Eliud Oloo
-
Patent number: 10751411Abstract: Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.Type: GrantFiled: July 30, 2019Date of Patent: August 25, 2020Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.Inventors: William Jacobs, Jr., Pablo A. Gonzalez Munoz, Betsy Herold, Christopher Petro
-
Patent number: 10744179Abstract: This invention relates to the use of an agent capable of inhibiting IL-36 proteolytic processing for the treatment and/or reduction of inflammation in a subject. Advantageously, the agent prevents the production of a biologically active IL-36 to prevent and/or reduce the pro-inflammatory effects of IL-36. The invention also relates to a method for treatment and/or reduction of inflammation and compositions for treating and/or reducing inflammation.Type: GrantFiled: September 18, 2015Date of Patent: August 18, 2020Assignee: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLYInventors: Seamus J. Martin, Conor Henry, Graeme Sullivan
-
Patent number: 10718771Abstract: Disclosed herein are recombinant baculoviruses suitable for detecting the presence of arthropod-borne viruses in a biological sample of a test subject. The information derived from the detection may also be used to render a diagnosis on whether the test subject is infected with the arthropod-borne viruses or not, so that proper course of treatment may be assigned to the subject.Type: GrantFiled: February 9, 2018Date of Patent: July 21, 2020Assignee: Chung Yuan Christian UniversityInventors: Tzong-Yuan Wu, Szu-Cheng Kuo, Pei-Yun Shu, Chang-Chi Lin, Der-Jiang Chiao, Ying-Ju Chen, Yi-Ting Lin, Shu-Fen Chang, Chien-Ling Su
-
Patent number: 10675345Abstract: Disclosed are recombinant chimeric influenza virus vaccines and live attenuated influenza virus (LAIV) vaccines expressing foreign (RSV) neutralizing epitopes or conserved M2e epitopes that are capable of providing broader cross-protection against influenza virus and/or protecting against respiratory syncytial virus (RSV) without vaccine-enhanced RSV disease (ERD).Type: GrantFiled: December 30, 2015Date of Patent: June 9, 2020Assignee: Georgia State University Research Foundation, Inc.Inventors: Sang-Moo Kang, Yu-Na Lee, Min-Chul Kim
-
Patent number: 10669315Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.Type: GrantFiled: June 9, 2016Date of Patent: June 2, 2020Assignee: Hookipa Biotech GmbHInventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
-
Patent number: 10617752Abstract: The present invention relates to canine influenza virus strains, and vaccines and compositions. The present invention also relates to reagents and methods allowing their detection, methods of vaccination as well as methods of producing these reagents and vaccines.Type: GrantFiled: June 23, 2016Date of Patent: April 14, 2020Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.Inventors: Yu-Wei Chiang, David Cureton, Herve Poulet
-
Patent number: 10568908Abstract: The invention relates to methods of treating an EBV-LPD (Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD, comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells.Type: GrantFiled: May 11, 2016Date of Patent: February 25, 2020Assignee: Memorial Sloan Kettering Cancer CenterInventors: Richard John O'Reilly, Susan Elizabeth Prockop, Aisha Nasreen Hasan, Ekaterina Doubrovina
-
Patent number: 10563222Abstract: The present invention provides for functional chimeric gene regulatory units capable of driving strong and sustained heterologous gene expression.Type: GrantFiled: June 17, 2015Date of Patent: February 18, 2020Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Yuansheng Yang, Cheng Leong Steven Ho, Shiyi Goh Fang
-
Patent number: 10550379Abstract: Engineered fusion proteins comprising a self-excising degron for controlling protein production are disclosed. In particular, the inventors have constructed fusion proteins comprising a degron connected to a protein of interest through a cleavable linker comprising a hepatitis C virus (HCV) protease site. The degron can be removed from the protein of interest by a czs-encoded HCV protease such that the protein of interest can be produced with minimal structural modification. Clinically available HCV protease inhibitors can be used to block protease cleavage such that the degron is retained after inhibitor addition on subsequently synthesized protein copies. The degron when attached causes rapid degradation of the linked protein. Such fusions of a degron to a protein of interest will be especially useful when control over protein production with minimal structural modification is desired.Type: GrantFiled: June 28, 2016Date of Patent: February 4, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Michael Z. Lin, Hokyung Chung, Conor Jacobs
-
Patent number: 10519517Abstract: The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single-stranded RNA virus (MPV) within the subfamily Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus and components thereof.Type: GrantFiled: December 28, 2018Date of Patent: December 31, 2019Assignees: VIRONOVATIVE BV, ERASMUS UNIVERSITY MEDICAL CENTERInventors: Jan Cornelius De Jong, Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Jan Groen
-
Patent number: 10513543Abstract: The present invention provides an antigen chimera, comprising: a fusion protein of an antigen and a mucosal immune adjuvant protein monomer capable of forming a multimer; and the mucosal immune adjuvant protein monomer capable of forming the multimer; wherein the mucosal immune adjuvant protein monomer capable of forming the multimer is one selected from cholera toxin B subunit (CTB) and E. coli heat-labile enterotoxin B subunit (LTB), the multimer is a pentamer, and in the chimera the molar ratio between the fusion protein and the mucosal immune adjuvant protein monomer capable of forming multimers is 1:4. In the present invention, a characteristic that a mucosal immune adjuvant protein can form a pentamer is used to form a chimeric structure, so as to form an antigen having a higher potency. Moreover, a mucosal immune adjuvant protein is used to improve an immune effect, so as to improve an effect of enhancing antigen immunogenicity.Type: GrantFiled: July 30, 2014Date of Patent: December 24, 2019Assignee: SHANGHAI UNITED CELL BIOTECHNOLOGY CO., LTD.Inventors: Keryin Lee, Yuhong Geng
-
Patent number: 10501733Abstract: The application discloses multimeric assemblies including multiple oligomeric substructures, where each oligomeric substructure includes multiple proteins that self-interact around at least one axis of rotational symmetry, where each protein includes one or more polypeptide-polypeptide interface (“O interface”); and one or more polypeptide domain that is capable of effecting membrane scission and release of an enveloped multimeric assembly from a cell by recruiting the ESCRT machinery to the site of budding by binding to one or more proteins in the eukaryotic ESCRT complex (“L domain”); and where the multimeric assembly includes one or more subunits comprising one or more polypeptide domain that is capable of interacting with a lipid bilayer (“M domain”), as well as membrane-enveloped versions of the multimeric assemblies.Type: GrantFiled: February 29, 2016Date of Patent: December 10, 2019Assignees: University of Washington, University of Utah Research FoundationInventors: Neil King, Wesley Sundquist, Joerg Votteler, Yang Hsia, David Baker, Jacob Bale, Marc Lajoie, Gabriel Butterfield, Elizabeth Gray, Daniel Stetson
-
Patent number: 10487332Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.Type: GrantFiled: July 6, 2011Date of Patent: November 26, 2019Assignee: GlaxoSmithKline Biologicals SAInventor: Andrew Geall
-
Patent number: 10485864Abstract: Provided herein are optimized, recombinant influenza HA polypeptides that elicit immune responses. Also provided are compositions and kits comprising the optimized HA polypeptides as well as methods of making and using the optimized HA polypeptides.Type: GrantFiled: September 21, 2016Date of Patent: November 26, 2019Assignee: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Ted Milburn Ross, Terianne Maiko Wong, Donald Martin Carter, Jr.
-
Patent number: 10478489Abstract: The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (CIV) and CIV-related pathology. The present invention is based in part upon the discovery that various mutations in segment 1 and segment 2 of the CIV genome, thereby encoding mutant PB2 and PB1 protein, render the virus to be temperature-sensitive.Type: GrantFiled: August 19, 2016Date of Patent: November 19, 2019Assignees: University of Rochester, Cornell UniversityInventors: Luis Martinez-Sobrido, Aitor Nogales-Gonzalez, Colin Parrish
-
Patent number: 10478490Abstract: This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of impeding immune evasion by HSV thereby vaccinating a subject against HSV and treating, suppressing, inhibiting, and/or reducing an incidence of an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention.Type: GrantFiled: November 13, 2008Date of Patent: November 19, 2019Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Harvey Friedman, Sita Awasthi, John Lubinski
-
Patent number: 10434165Abstract: The present invention encompasses FCV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FCV antigens. The invention also encompasses recombinant vectors encoding and expressing FCV antigens, epitopes or immunogens which can be used to protect animals against FCV infection.Type: GrantFiled: August 16, 2016Date of Patent: October 8, 2019Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.Inventors: Herve Poulet, Frédéric Reynard
-
Patent number: 10408836Abstract: Provided herein is a method of detecting the presence of influenza virus in a sample while minimizing false positives due to presence of one or more other pathogens in the sample, the method including measuring the enzymatic activity of neuraminidase (NA) in the sample under one or more differentiating conditions selected from the group consisting of pH, binding to anti-NanA antibody, size exclusion, hemagglutinin (HA) binding, chemical inhibition, and combinations thereof.Type: GrantFiled: October 5, 2016Date of Patent: September 10, 2019Assignees: University of Cincinnati, MicrobeCapture, LLCInventors: Alison A. Weiss, Karen Melissa Gallegos Villalobos, David Ralph
-
Patent number: 10398773Abstract: The present invention relates to a novel porcine parvovirus, to proteins of the virus and to vaccines based upon the virus and proteins thereof. The invention also relates to DNA fragments comprising a gene of the virus and to DNA vaccines based upon genes of the virus. Further the invention relates to antibodies that are reactive with the novel virus and to diagnostic tests for the detection of the virus or antibodies against the virus.Type: GrantFiled: April 16, 2015Date of Patent: September 3, 2019Assignee: Intervet Inc.Inventors: Lars Guelen, Ad de Groof, Carla Christina Schrier, Martin Deijs, Cornelia Maria Hoek Van Der
-
Patent number: 10391164Abstract: Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.Type: GrantFiled: December 14, 2016Date of Patent: August 27, 2019Assignee: IMMUNE DESIGN CORP.Inventors: Thomas W. Dubensky, Jr., Nancy A. Hosken, Scott H. Robbins, Margaret D. Moore
-
Patent number: 10383936Abstract: In this study, for the first time, protective efficacy of gD against ILTV challenge was evaluated. Immunization with recombinant Newcastle disease virus expressing ILTV gD induced a higher level of neutralizing antibodies and offered complete protection to chickens against lethal ILTV challenge. Uses of recombinant NDV as a vaccine vector are also described.Type: GrantFiled: July 21, 2014Date of Patent: August 20, 2019Assignee: University of Maryland, College ParkInventors: Siba K. Samal, Mallikarjuna Kanabagatte Basavarajappa, Sweety Samal
-
Patent number: 10350288Abstract: The present disclosure provides certain combinations of immunogenic compositions against HSV-2 and antiviral therapy. The vaccines can be used therapeutically and/or prophylactically.Type: GrantFiled: September 27, 2017Date of Patent: July 16, 2019Assignee: Genocea Biosciences, Inc.Inventor: Seth Vollmer Hetherington
-
Patent number: 10342864Abstract: Methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with human immunodeficiency virus (HIV) or has been the recipient of a solid organ transplant.Type: GrantFiled: June 24, 2016Date of Patent: July 9, 2019Assignees: Memorial Sloan Kettering Cancer Center, Cornell UniversityInventors: Richard John O'Reilly, Susan Elizabeth Prockop, Ekaterina Doubrovina, Guenther Koehne, Aisha Nasreen Hasan, Szilard Kiss
-
Patent number: 10329537Abstract: The invention provides reassortant influenza strains.Type: GrantFiled: June 6, 2014Date of Patent: June 25, 2019Assignees: Seqirus UK Limited, Synthetic Genomics, Inc.Inventors: Peter Mason, Pirada Suphaphiphat, Raul Gomila, Philip Dormitzer
-
Patent number: 10323068Abstract: The invention relates to a group of synthetic polypeptides, derived from the pre-S1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies.Type: GrantFiled: November 18, 2015Date of Patent: June 18, 2019Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Philippe Gripon, Stephan Urban
-
Patent number: 10316295Abstract: Provided are modified virus-like particles (VLPs) of paramyxoviruses, compositions containing them, methods of using the VLPs for delivery of any particular protein of interest to any of a variety of cells, kits that contain expression vectors for making, using and detecting VLPs, and methods for screening for anti-viral compounds using the VLPs. The modified VLPs contain a contiguous recombinant polypeptide that contains i) all or a segment of a C-terminal domain of a paramyxovirus nucleocapsid protein and ii) a polypeptide sequence of a distinct protein. Non-covalent complexes of paramyxovirus M protein and fusion proteins that contain a C-terminal domain of a paramyxovirus nucleocapsid protein and a polypeptide sequence of a distinct protein are provided, as are non-covalent complexes of cells, and cell receptors, with modified VLPs.Type: GrantFiled: December 19, 2016Date of Patent: June 11, 2019Assignee: The Penn State Research FoundationInventors: Anthony Paul Schmitt, Phuong Tieu Schmitt, Greeshma Vivekananda Ray
-
Patent number: 10308689Abstract: Dengue virus (DV) peptides, including T cell epitopes, structural and non-structural (NS) polypeptide sequences, subsequences and modifications thereof, nucleotide sequences encoding such peptides, and compositions including such peptides and encoding nucleotide sequences, and cells expressing such peptides, are provided. Such DV peptides, nucleotide sequences and compositions, can be used to elicit, stimulate, induce, promote, increase, enhance or activate an anti-DV CD8+ T cell response or an anti-DV CD4+ T cell response. Such peptides, nucleotide sequences and compositions can also be used for and in methods of vaccination/immunization of a subject against Dengue virus (DV) (e.g., to provide protection against DV infection and/or pathology), and for treatment of a subject in need thereof, for example, treatment of the subject for a Dengue virus (DV) infection or pathology.Type: GrantFiled: July 15, 2015Date of Patent: June 4, 2019Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGYInventors: Sujan Shresta, Lauren Yauch, Alessandro Sette, Daniela Weiskopf
-
Patent number: 10248758Abstract: Synthetic nanostructures, proteins that are useful, for example, in making synthetic nanostructures, and methods for designing such synthetic nanostructures are disclosed herein.Type: GrantFiled: February 7, 2014Date of Patent: April 2, 2019Assignee: University of Washington Through its Center for CommercializationInventors: David Baker, Neil King, Jacob Bale, William Sheffler
-
Patent number: 10232030Abstract: Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV6 E6E7, HPV11 E6E7, HPV16 E6E7, HPV18 E6E7, HPV31 E6E7, HPV33 E6E7, HPV39 E6E7, HPV45 E6E7, HPV52 E6E7, and HPV58 E6E7. Pharmaceutical composition, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.Type: GrantFiled: March 12, 2014Date of Patent: March 19, 2019Assignees: INOVIO PHARMACEUTICALS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: David B. Weiner, Jian Yan
-
Patent number: 10220086Abstract: The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides. Co-administration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.Type: GrantFiled: December 18, 2015Date of Patent: March 5, 2019Assignees: OREGON HEALTH & SCIENCE UNIVERSITY, SANOFI PASTEUR, INC.Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Christopher Austin Darby, Harold Kleanthous
-
Patent number: 10206996Abstract: The present application relates to the field of human immunology, in particular, a herpes simplex virus (HSV) vaccine. The subunit vaccine composition comprises isolated surface glycoproteins from herpes simplex viruses, fusion proteins or fragments thereof mixed in varied combination with a nanoemulsion, which is a potent immune enhancer.Type: GrantFiled: August 22, 2012Date of Patent: February 19, 2019Assignee: NanoBio CorporationInventors: Ali I. Fattom, Jakub Simon, James R. Baker, Jr., Tarek Hamouda, Vira Bitko
-
Patent number: 10192025Abstract: The present invention relates to the use of rotavirus particles for displaying a heterologous protein, alone or in complex with another molecule. The invention further relates to methods that employ these modified rotavirus particles to rapidly determine the structure of the heterologous protein or the complex using cryo-electron microscopy (cryo-EM). The invention also relates to a method of immunizing a patient, wherein said method comprises administering to the patient the modified rotavirus particles of the invention.Type: GrantFiled: July 8, 2014Date of Patent: January 29, 2019Assignee: Novartis AGInventors: Philip R. Dormitzer, Nikolaus Grigorieff, Stephen Harrison, Junhua Pan, Ethan Settembre
-
Patent number: 10117922Abstract: Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. Herein, we report novel, naturally processed and presented MHC class I restricted epitopes, a subset of which binds to and activates T cells in both an HLA-A2 and HLA-A24 restricted manner.Type: GrantFiled: May 11, 2015Date of Patent: November 6, 2018Assignee: Emergex Vaccines Holding Ltd.Inventor: Ramila Philip
-
Patent number: 10080796Abstract: Described herein are influenza virus-like particles (VLPs) that display on truncated, re-engineered or remodeled HA molecules on their surface. Also described are methods of making and using these VLPs.Type: GrantFiled: May 6, 2016Date of Patent: September 25, 2018Assignee: TECHNOVAX, INC.Inventors: Jose M. Galarza, George R. Martin
-
Patent number: 10080798Abstract: The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs provided by the invention are formed by the CPV VP2 protein. Further, the invention broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.Type: GrantFiled: September 14, 2016Date of Patent: September 25, 2018Assignee: MERIAL INC.Inventors: Frederic David, Zahia Hannas-Djebbara, Herve Poulet, Jules Maarten Minke
-
Patent number: 10046026Abstract: This invention relates, e.g., to a virus-like particle (VLP) composition assembled from a chimeric polypeptide comprising a papilloma virus (e.g., human papillomavirus, or HPV) L1 major capsid protein, into which is inserted a surface-displayed peptide comprising a neutralizing epitope of a papillomavirus L2 protein. Vaccine compositions comprising the VLP are described, as well as methods for inducing an immune response (e.g., vaccinating) a subject against papilloma virus, using the VLP, and kits comprising the VLP, for carrying out a method of the invention.Type: GrantFiled: October 5, 2015Date of Patent: August 14, 2018Assignee: The Johns Hopkins UniversityInventors: Richard B. S. Roden, Reinhard Kirnbauer, Christina Schellenbacher
-
Patent number: 9987349Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: GrantFiled: March 21, 2016Date of Patent: June 5, 2018Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael B Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
-
Patent number: 9981033Abstract: The present invention encompasses recombinant porcine reproductive and respiratory syndrome virus (PRRSV) vaccines or compositions. In particular, the invention encompasses recombinant adenovirus vectors encoding and expressing PRRSV gp2, gp3, gp4, gp5a, gp5 and/or E antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals from PRRSV.Type: GrantFiled: June 23, 2016Date of Patent: May 29, 2018Assignee: MERIAL INC.Inventors: Teshome Mebatsion, Aemro Kassa, Taejoong Kim
-
Patent number: 9974849Abstract: Peptides and compositions for a therapeutic vaccine to treat persons infected with human papilloma virus are presented. Methods of using the compositions and treating persons infected with human papilloma virus, including those at risk of cancer or already with cancer from human papilloma virus, are presented.Type: GrantFiled: October 11, 2014Date of Patent: May 22, 2018Assignee: Bioventures, LLCInventors: Mayumi Nakagawa, Byeong S. Chang
-
Patent number: 9962436Abstract: The present disclosure provides fusion proteins that incorporate unique mechanisms for multimerizmg antigens to enhance their immunogenicity. The fusion proteins comprise at least two antigens, or other vaccine related proteins, separated by a linker sequence and an oligomerization domain. When expressed, the fusion protein forms a muKimeric protein complex, This approach can be used to muHimeri?.e a single antigen/protein or to create multimers comprising two or more different antigens/proteins. Also provided are nucleic acids encoding the fusion proteins, Yet another aspect is directed to methods of inducing or suppressing an immune response in a subject by administering to the subject a vaccine composition comprising a fusion protein or nucleic acid encoding the fusion protein, optionally without using an adjuvant.Type: GrantFiled: July 26, 2013Date of Patent: May 8, 2018Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.Inventors: James J Mond, Clifford M. Snapper, Xinle Cui
-
Patent number: 9945856Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.Type: GrantFiled: August 13, 2014Date of Patent: April 17, 2018Assignee: AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V.Inventor: Cornelia Maria van der Hoek
-
Patent number: 9931393Abstract: Methods of eliciting an immune response to a JC polyomavirus (JCV) by administering an effective amount of an immunogenic composition including an isolated JCV VP1 polypeptide or a nucleic acid encoding the VP1 polypeptide to a subject are provided. VP1 polypeptides and immunogenic compositions suitable for use in the methods are provided, including JCV genotype 2 VP1 polypeptides and/or JCV genotype 3 polypeptides. Methods of identifying a subject at risk of developing progressive multifocal leukoencephalopathy (PML) are also provided. In some embodiments, the methods include obtaining a biological sample from a subject, detecting presence or absence of JCV neutralizing antibodies in the sample from the subject, and identifying that the subject is at risk of developing PML if there is an absence of detectable JCV neutralizing antibodies in the sample from the subject.Type: GrantFiled: December 19, 2014Date of Patent: April 3, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Christopher B. Buck, Upasana Ray, Diana V. Pastrana
-
Patent number: 9913894Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.Type: GrantFiled: July 13, 2015Date of Patent: March 13, 2018Assignee: MedImmune, LLCInventors: Guillermo Tous, Mark Schenerman, Jose Casas-Finet, Ziping Wei, David Pfarr
-
Patent number: 9901632Abstract: An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.Type: GrantFiled: October 21, 2013Date of Patent: February 27, 2018Assignee: The Council of the Queensland Institute of Medical ResearchInventors: Rajiv Khanna, Dasari Vijayendra
-
Patent number: 9890368Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.Type: GrantFiled: October 21, 2014Date of Patent: February 13, 2018Assignees: European Molecular Biology Laboratory (EMBL), Centre National de la Recherche Scientifique, Universite Grenoble AlpesInventors: Denis Bouvier, Thibaut Crepin, Rob Ruigrok, Aelxander Dias, Stephen Cusack
-
Patent number: 9884103Abstract: Disclosed are interactions between different betanodaviruses during infection of cells “in vitro” and in European sea bass. More specifically, fish administered striped jack nervous necrosis viruses (SJNNV), which are then exposed to red-spotted grouper nervous necrosis viruses (RGNNV), have fewer symptoms of disease associated with RGNNV and/or increased survival as compared to fish not administered SJNNV prior to exposure to RGNNV.Type: GrantFiled: May 26, 2014Date of Patent: February 6, 2018Assignee: Elanco Tiergesundheit AGInventors: Juan Jose Borrego, Carlos Carballo Perez, Maria Del Carmen Alonso, Esther Garcia Rosado, Benjamin Lopez-Jimena, Jose F Rodriguez
-
Patent number: 9878031Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject using trivalent dengue virus vaccine compositions. In some embodiments, more than one vaccine composition may be administered to a subject in different anatomical locations in order to induce a rapid response to at least three of four dengue virus serotypes. In certain embodiments, administration of a trivalent dengue virus vaccine composition can be combined with administration of a monovalent dengue virus vaccine composition.Type: GrantFiled: December 7, 2013Date of Patent: January 30, 2018Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Joseph N. Brewoo, Jorge E. Osorio, Charalambos D. Partidos
-
Patent number: 9782474Abstract: Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. Highly effective vaccines and immunogenic compositions against HSV-2, which can be used therapeutically or prophylactically, are described.Type: GrantFiled: November 23, 2011Date of Patent: October 10, 2017Assignee: Genocea Biosciences, Inc.Inventors: Deborah Long, Jessica Flechtner, Mojca Skoberne